Cargando…
Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity
Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly s...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972997/ https://www.ncbi.nlm.nih.gov/pubmed/31584233 http://dx.doi.org/10.1002/anie.201909857 |
_version_ | 1783489952566214656 |
---|---|
author | Quambusch, Lena Landel, Ina Depta, Laura Weisner, Jörn Uhlenbrock, Niklas Müller, Matthias P. Glanemann, Franziska Althoff, Kristina Siveke, Jens T. Rauh, Daniel |
author_facet | Quambusch, Lena Landel, Ina Depta, Laura Weisner, Jörn Uhlenbrock, Niklas Müller, Matthias P. Glanemann, Franziska Althoff, Kristina Siveke, Jens T. Rauh, Daniel |
author_sort | Quambusch, Lena |
collection | PubMed |
description | Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure‐guided approach for the design of structurally diverse and pharmacologically beneficial covalent‐allosteric modifiers, which enabled an investigation of the isoform‐specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform‐selective covalent‐allosteric Akt inhibitors that emerged from this approach showed a conclusive structure–activity relationship and broke ground in the development of selective probes to delineate the isoform‐specific functions of Akt kinases. |
format | Online Article Text |
id | pubmed-6972997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69729972020-01-27 Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity Quambusch, Lena Landel, Ina Depta, Laura Weisner, Jörn Uhlenbrock, Niklas Müller, Matthias P. Glanemann, Franziska Althoff, Kristina Siveke, Jens T. Rauh, Daniel Angew Chem Int Ed Engl Communications Isoforms of protein kinase Akt are involved in essential processes including cell proliferation, survival, and metabolism. However, their individual roles in health and disease have not been thoroughly evaluated. Thus, there is an urgent need for perturbation studies, preferably mediated by highly selective bioactive small molecules. Herein, we present a structure‐guided approach for the design of structurally diverse and pharmacologically beneficial covalent‐allosteric modifiers, which enabled an investigation of the isoform‐specific preferences and the important residues within the allosteric site of the different isoforms. The biochemical, cellular, and structural evaluations revealed interactions responsible for the selective binding profiles. The isoform‐selective covalent‐allosteric Akt inhibitors that emerged from this approach showed a conclusive structure–activity relationship and broke ground in the development of selective probes to delineate the isoform‐specific functions of Akt kinases. John Wiley and Sons Inc. 2019-11-08 2019-12-19 /pmc/articles/PMC6972997/ /pubmed/31584233 http://dx.doi.org/10.1002/anie.201909857 Text en © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Communications Quambusch, Lena Landel, Ina Depta, Laura Weisner, Jörn Uhlenbrock, Niklas Müller, Matthias P. Glanemann, Franziska Althoff, Kristina Siveke, Jens T. Rauh, Daniel Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title | Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title_full | Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title_fullStr | Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title_full_unstemmed | Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title_short | Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity |
title_sort | covalent‐allosteric inhibitors to achieve akt isoform‐selectivity |
topic | Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972997/ https://www.ncbi.nlm.nih.gov/pubmed/31584233 http://dx.doi.org/10.1002/anie.201909857 |
work_keys_str_mv | AT quambuschlena covalentallostericinhibitorstoachieveaktisoformselectivity AT landelina covalentallostericinhibitorstoachieveaktisoformselectivity AT deptalaura covalentallostericinhibitorstoachieveaktisoformselectivity AT weisnerjorn covalentallostericinhibitorstoachieveaktisoformselectivity AT uhlenbrockniklas covalentallostericinhibitorstoachieveaktisoformselectivity AT mullermatthiasp covalentallostericinhibitorstoachieveaktisoformselectivity AT glanemannfranziska covalentallostericinhibitorstoachieveaktisoformselectivity AT althoffkristina covalentallostericinhibitorstoachieveaktisoformselectivity AT sivekejenst covalentallostericinhibitorstoachieveaktisoformselectivity AT rauhdaniel covalentallostericinhibitorstoachieveaktisoformselectivity |